Keen Vision Acquisition in an 8-K said it entered into a non-binding letter of intent with a clinical stage biopharmaceutical company based in Boston.
The target is focused on the research, development, manufacture and use of a human stem cell-based bioengineering technology platform for novel drug discovery; and the development of next-generation cell and gene therapies for a range of difficult-to-treat or incurable diseases. With a pipeline of therapeutic candidates, several of the target’s experimental gene therapies have obtained U.S. Food and Drug Administration Investigational New Drug approvals as ongoing clinical trials at multiple premier hospitals in the U.S. with active patient enrollments, according to the filing.
The SPAC raised $130 million in a July 2023 IPO. Read more.
